← Patent-cliff monitor small molecule ELIQUIS APIXABAN
Loss of exclusivity August 2031 latest FDA-listed patent expiry
Company BRISTOL MYERS SQUIBB CO PHARMACEUTICAL RESEARCH INSTITUTE
Drug detail Brand name ELIQUIS Active ingredient APIXABAN Strength 5MG Dosage form TABLET Route ORAL Modality Small molecule FDA approval December 2012 Marketing status RX
Listed patents Patent Expires Type 9326945*PED August 2031 — 9326945 February 2031 product 6967208*PED May 2027 — 6967208 November 2026 substance, product
Regulatory exclusivity Code Expires PED October 2028 NPP April 2028
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.